Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 174

1.

Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review.

de Filette JMK, Pen JJ, Decoster L, Vissers T, Bravenboer B, Van der Auwera BJ, Gorus F, Roep BO, Aspeslagh S, Neyns B, Velkeniers B, Kharagjitsingh AV.

Eur J Endocrinol. 2019 Jul 1. pii: EJE-19-0291.R1. doi: 10.1530/EJE-19-0291. [Epub ahead of print]

2.

Combined Analysis of GAD65, miR-375, and Unmethylated Insulin DNA Following Islet Transplantation in Patients With T1D.

Roels S, Costa OR, Tersey SA, Stangé G, De Smet D, Balti EV, Gillard P, Keymeulen B, Ling Z, Pipeleers DG, Gorus FK, Mirmira RG, Martens GA.

J Clin Endocrinol Metab. 2019 Feb 1;104(2):451-460. doi: 10.1210/jc.2017-02520.

3.

SLC30A8 polymorphism and BMI complement HLA-A*24 as risk factors for poor graft function in islet allograft recipients.

Balke EM, Demeester S, Lee D, Gillard P, Hilbrands R, Van de Velde U, Van der Auwera BJ, Ling Z, Roep BO, Pipeleers DG, Keymeulen B, Gorus FK.

Diabetologia. 2018 Jul;61(7):1623-1632. doi: 10.1007/s00125-018-4609-z. Epub 2018 Apr 20.

PMID:
29679103
4.

Accelerated Progression to Type 1 Diabetes in the Presence of HLA-A*24 and -B*18 Is Restricted to Multiple Islet Autoantibody-Positive Individuals With Distinct HLA-DQ and Autoantibody Risk Profiles.

Balke EM, Balti EV, Van der Auwera B, Weets I, Costa O, Demeester S, Abrams P, Casteels K, Coeckelberghs M, Tenoutasse S, Keymeulen B, Pipeleers DG, Gorus FK; Belgian Diabetes Registry.

Diabetes Care. 2018 May;41(5):1076-1083. doi: 10.2337/dc17-2462. Epub 2018 Mar 15.

PMID:
29545461
5.

An analytical comparison of three immunoassay platforms for subpicomolar detection of protein biomarker GAD65.

Costa OR, Verhaeghen K, Roels S, Stangé G, Ling Z, Pipeleers D, Gorus FK, Martens GA.

PLoS One. 2018 Mar 8;13(3):e0193670. doi: 10.1371/journal.pone.0193670. eCollection 2018.

6.

A novel LIPS assay for insulin autoantibodies.

Liberati D, Wyatt RC, Brigatti C, Marzinotto I, Ferrari M, Bazzigaluppi E, Bosi E, Gillard BT, Gillespie KM, Gorus F, Weets I, Balti E, Piemonti L, Achenbach P, Williams AJK, Lampasona V.

Acta Diabetol. 2018 Mar;55(3):263-270. doi: 10.1007/s00592-017-1082-y. Epub 2018 Jan 5.

PMID:
29305766
7.

Twenty-Year Progression Rate to Clinical Onset According to Autoantibody Profile, Age, and HLA-DQ Genotype in a Registry-Based Group of Children and Adults With a First-Degree Relative With Type 1 Diabetes.

Gorus FK, Balti EV, Messaaoui A, Demeester S, Van Dalem A, Costa O, Dorchy H, Mathieu C, Van Gaal L, Keymeulen B, Pipeleers DG, Weets I; Belgian Diabetes Registry.

Diabetes Care. 2017 Aug;40(8):1065-1072. doi: 10.2337/dc16-2228.

PMID:
28701370
8.

Correction: Prediction of Impending Type 1 Diabetes through Automated Dual-Label Measurement of Proinsulin:C-Peptide Ratio.

Van Dalem A, Demeester S, Balti EV, Keymeulen B, Gillard P, Lapauw B, De Block C, Abrams P, Weber E, Vermeulen I, De Pauw P, Pipeleers D, Weets I, Gorus FK; Belgian Diabetes Registry.

PLoS One. 2017 Jun 1;12(6):e0179108. doi: 10.1371/journal.pone.0179108. eCollection 2017.

9.

Prediction of Impending Type 1 Diabetes through Automated Dual-Label Measurement of Proinsulin:C-Peptide Ratio.

Van Dalem A, Demeester S, Balti EV, Keymeulen B, Gillard P, Lapauw B, De Block C, Abrams P, Weber E, Vermeulen I, De Pauw P, Pipeleers D, Weets I, Gorus FK; Belgian Diabetes Registry.

PLoS One. 2016 Dec 1;11(12):e0166702. doi: 10.1371/journal.pone.0166702. eCollection 2016. Erratum in: PLoS One. 2017 Jun 1;12 (6):e0179108.

10.

Evaluation of the Sebia Capillarys 3 Tera and the Bio-Rad D-100 Systems for the Measurement of Hemoglobin A1c.

Herpol M, Lanckmans K, Van Neyghem S, Clement P, Crevits S, De Crem K, Gorus FK, Weets I.

Am J Clin Pathol. 2016 Jul;146(1):67-77. doi: 10.1093/ajcp/aqw081. Epub 2016 Jun 29.

PMID:
27357293
11.

HLA-A*24 Carrier Status and Autoantibody Surges Posttransplantation Associate With Poor Functional Outcome in Recipients of an Islet Allograft.

Demeester S, Balke EM, Van der Auwera BJ, Gillard P, Hilbrands R, Lee D, Van de Velde U, Ling Z, Roep BO, Pipeleers DG, Gorus FK, Keymeulen B.

Diabetes Care. 2016 Jun;39(6):1060-4. doi: 10.2337/dc15-2768. Epub 2016 Apr 26.

PMID:
27208324
12.

Development of an Enhanced Sensitivity Bead-Based Immunoassay for Real-Time In Vivo Detection of Pancreatic β-Cell Death.

Costa OR, Stangé G, Verhaeghen K, Brackeva B, Nonneman E, Hampe CS, Ling Z, Pipeleers D, Gorus FK, Martens GA.

Endocrinology. 2015 Dec;156(12):4755-60. doi: 10.1210/en.2015-1636. Epub 2015 Oct 2.

13.

Relationship between glycaemic variability and hyperglycaemic clamp-derived functional variables in (impending) type 1 diabetes.

Van Dalem A, Demeester S, Balti EV, Decochez K, Weets I, Vandemeulebroucke E, Van de Velde U, Walgraeve A, Seret N, De Block C, Ruige J, Gillard P, Keymeulen B, Pipeleers DG, Gorus FK; Belgian Diabetes Registry.

Diabetologia. 2015 Dec;58(12):2753-64. doi: 10.1007/s00125-015-3761-y. Epub 2015 Sep 26.

PMID:
26409458
14.

Plasma GAD65, a Marker for Early β-Cell Loss After Intraportal Islet Cell Transplantation in Diabetic Patients.

Ling Z, De Pauw P, Jacobs-Tulleneers-Thevissen D, Mao R, Gillard P, Hampe CS, Martens GA, In't Veld P, Lernmark Å, Keymeulen B, Gorus F, Pipeleers D.

J Clin Endocrinol Metab. 2015 Jun;100(6):2314-21. doi: 10.1210/jc.2015-1216. Epub 2015 Mar 27.

15.

Potential of UCHL1 as biomarker for destruction of pancreatic beta cells.

Brackeva B, De Punt V, Kramer G, Costa O, Verhaeghen K, Stangé G, Sadones J, Xavier C, Aerts JM, Gorus FK, Martens GA.

J Proteomics. 2015 Mar 18;117:156-67. doi: 10.1016/j.jprot.2015.01.009. Epub 2015 Jan 29.

PMID:
25638021
16.

Preexisting insulin autoantibodies predict efficacy of otelixizumab in preserving residual β-cell function in recent-onset type 1 diabetes.

Demeester S, Keymeulen B, Kaufman L, Van Dalem A, Balti EV, Van de Velde U, Goubert P, Verhaeghen K, Davidson HW, Wenzlau JM, Weets I, Pipeleers DG, Gorus FK.

Diabetes Care. 2015 Apr;38(4):644-51. doi: 10.2337/dc14-1575. Epub 2015 Jan 12.

17.

Hyperglycemic clamp and oral glucose tolerance test for 3-year prediction of clinical onset in persistently autoantibody-positive offspring and siblings of type 1 diabetic patients.

Balti EV, Vandemeulebroucke E, Weets I, Van De Velde U, Van Dalem A, Demeester S, Verhaeghen K, Gillard P, De Block C, Ruige J, Keymeulen B, Pipeleers DG, Decochez K, Gorus FK; Belgian Diabetes Registry.

J Clin Endocrinol Metab. 2015 Feb;100(2):551-60. doi: 10.1210/jc.2014-2035. Epub 2014 Nov 18.

PMID:
25405499
18.

BMI is an important driver of β-cell loss in type 1 diabetes upon diagnosis in 10 to 18-year-old children.

Lauria A, Barker A, Schloot N, Hosszufalusi N, Ludvigsson J, Mathieu C, Mauricio D, Nordwall M, Van der Schueren B, Mandrup-Poulsen T, Scherbaum WA, Weets I, Gorus FK, Wareham N, Leslie RD, Pozzilli P.

Eur J Endocrinol. 2015 Feb;172(2):107-13. doi: 10.1530/EJE-14-0522. Epub 2014 Nov 6.

PMID:
25378371
19.

Evaluation of the Sebia CAPILLARYS 2 flex piercing for the measurement of HbA(1c) on venous and capillary blood samples.

Heylen O, Van Neyghem S, Exterbille S, Wehlou C, Gorus F, Weets I.

Am J Clin Pathol. 2014 Jun;141(6):867-77. doi: 10.1309/AJCPRU5QC2JBANSV.

PMID:
24838332
20.

Early alteration of kidney function in nonuremic type 1 diabetic islet transplant recipients under tacrolimus-mycophenolate therapy.

Gillard P, Rustandi M, Efendi A, Lee DH, Ling Z, Hilbrands R, Kuypers D, Mathieu C, Jacobs-Tulleneers-Thevissen D, Gorus F, Pipeleers D, Keymeulen B.

Transplantation. 2014 Aug 27;98(4):451-7. doi: 10.1097/TP.0000000000000086.

PMID:
24770614
21.

Clinical and biological characteristics of diabetic patients under age 40 in Cameroon: relation to autoantibody status and comparison with Belgian patients.

Asanghanwa M, Gorus FK, Weets I, der Auwera BV, Aminkeng F, Mbunwe E, Goubert P, Verhaeghen K, Sobngwi E, Wenzlau JM, Hutton JC, Pipeleers DG, Keymeulen B, Mbanya JC, van Schravendijk C.

Diabetes Res Clin Pract. 2014 Jan;103(1):97-105. doi: 10.1016/j.diabres.2013.11.013. Epub 2013 Nov 20.

22.

Predictors of progression to Type 1 diabetes: preparing for immune interventions in the preclinical disease phase.

Gorus FK, Keymeulen B, Veld PA, Pipeleers DG.

Expert Rev Clin Immunol. 2013 Dec;9(12):1173-83. doi: 10.1586/1744666X.2013.856757. Review.

PMID:
24215407
23.

Age-dependent decline of β-cell function in type 1 diabetes after diagnosis: a multi-centre longitudinal study.

Barker A, Lauria A, Schloot N, Hosszufalusi N, Ludvigsson J, Mathieu C, Mauricio D, Nordwall M, Van der Schueren B, Mandrup-Poulsen T, Scherbaum WA, Weets I, Gorus FK, Wareham N, Leslie RD, Pozzilli P.

Diabetes Obes Metab. 2014 Mar;16(3):262-7. doi: 10.1111/dom.12216. Epub 2013 Oct 29.

PMID:
24118704
24.

Minimal functional β-cell mass in intraportal implants that reduces glycemic variability in type 1 diabetic recipients.

Gillard P, Hilbrands R, Van de Velde U, Ling Z, Lee DH, Weets I, Gorus F, De Block C, Kaufman L, Mathieu C, Pipeleers D, Keymeulen B.

Diabetes Care. 2013 Nov;36(11):3483-8. doi: 10.2337/dc13-0128. Epub 2013 Sep 16.

25.

Alternative splicing and differential expression of the islet autoantigen IGRP between pancreas and thymus contributes to immunogenicity of pancreatic islets but not diabetogenicity in humans.

de Jong VM, Abreu JR, Verrijn Stuart AA, van der Slik AR, Verhaeghen K, Engelse MA, Blom B, Staal FJ, Gorus FK, Roep BO.

Diabetologia. 2013 Dec;56(12):2651-8. doi: 10.1007/s00125-013-3034-6. Epub 2013 Sep 13.

PMID:
24030068
26.

Predictive factors of allosensitization after immunosuppressant withdrawal in recipients of long-term cultured islet cell grafts.

Hilbrands R, Gillard P, Van der Torren CR, Ling Z, Verheyden S, Jacobs-Tulleneers-Thevissen D, Roep BO, Claas FH, Demanet C, Gorus FK, Pipeleers D, Keymeulen B.

Transplantation. 2013 Jul 27;96(2):162-9. doi: 10.1097/TP.0b013e3182977afc.

PMID:
23857001
27.

In antibody-positive first-degree relatives of patients with type 1 diabetes, HLA-A*24 and HLA-B*18, but not HLA-B*39, are predictors of impending diabetes with distinct HLA-DQ interactions.

Mbunwe E, Van der Auwera BJ, Weets I, Van Crombrugge P, Crenier L, Coeckelberghs M, Seret N, Decochez K, Vandemeulebroucke E, Gillard P, Keymeulen B, van Schravendijk C, Wenzlau JM, Hutton JC, Pipeleers DG, Gorus FK; Belgian Diabetes Registry.

Diabetologia. 2013 Sep;56(9):1964-70. doi: 10.1007/s00125-013-2951-8. Epub 2013 May 28.

28.

Sustained function of alginate-encapsulated human islet cell implants in the peritoneal cavity of mice leading to a pilot study in a type 1 diabetic patient.

Jacobs-Tulleneers-Thevissen D, Chintinne M, Ling Z, Gillard P, Schoonjans L, Delvaux G, Strand BL, Gorus F, Keymeulen B, Pipeleers D; Beta Cell Therapy Consortium EU-FP7.

Diabetologia. 2013 Jul;56(7):1605-14. doi: 10.1007/s00125-013-2906-0. Epub 2013 Apr 26.

PMID:
23620058
29.

Potential of protein phosphatase inhibitor 1 as biomarker of pancreatic β-cell injury in vitro and in vivo.

Jiang L, Brackeva B, Ling Z, Kramer G, Aerts JM, Schuit F, Keymeulen B, Pipeleers D, Gorus F, Martens GA.

Diabetes. 2013 Aug;62(8):2683-8. doi: 10.2337/db12-1507. Epub 2013 Apr 4.

30.

Sensitive and specific time-resolved fluorescence immunoassay of rat C-peptide for measuring hormone secretory and storage capacity of β-cells in vivo and in vitro.

van Genderen FT, Gorus FK, Pipeleers DG, van Schravendijk CF.

Endocrinology. 2013 May;154(5):1934-9. doi: 10.1210/en.2012-2167. Epub 2013 Mar 24.

PMID:
23525244
31.

LC-MS/MS identification of doublecortin as abundant beta cell-selective protein discharged by damaged beta cells in vitro.

Jiang L, Brackeva B, Stangé G, Verhaeghen K, Costa O, Couillard-Després S, Rotheneichner P, Aigner L, Van Schravendijk C, Pipeleers D, Ling Z, Gorus F, Martens GA.

J Proteomics. 2013 Mar 27;80:268-80. doi: 10.1016/j.jprot.2012.12.031. Epub 2013 Jan 19.

PMID:
23337804
32.

Long-term stability of laboratory tests and practical implications for quality management.

Van Houcke SK, Stepman HC, Thienpont LM, Fiers T, Stove V, Couck P, Anckaert E, Gorus F.

Clin Chem Lab Med. 2013 Jun;51(6):1227-31. doi: 10.1515/cclm-2012-0820.

PMID:
23337057
33.

Screening for insulinoma antigen 2 and zinc transporter 8 autoantibodies: a cost-effective and age-independent strategy to identify rapid progressors to clinical onset among relatives of type 1 diabetic patients.

Gorus FK, Balti EV, Vermeulen I, Demeester S, Van Dalem A, Costa O, Dorchy H, Tenoutasse S, Mouraux T, De Block C, Gillard P, Decochez K, Wenzlau JM, Hutton JC, Pipeleers DG, Weets I; Belgian Diabetes Registry.

Clin Exp Immunol. 2013 Jan;171(1):82-90. doi: 10.1111/j.1365-2249.2012.04675.x.

34.

Enzymatic pyruvate measurement by Cobas 6000 open channel assay.

Van den Bossche D, Schiettecatte J, Vekens E, De Smet D, Gorus FK, Martens GA.

Clin Lab. 2012;58(9-10):1091-5.

PMID:
23163130
35.

HLA-A*24 is an independent predictor of 5-year progression to diabetes in autoantibody-positive first-degree relatives of type 1 diabetic patients.

Mbunwe E, Van der Auwera BJ, Vermeulen I, Demeester S, Van Dalem A, Balti EV, Van Aken S, Derdelinckx L, Dorchy H, De Schepper J, van Schravendijk C, Wenzlau JM, Hutton JC, Pipeleers D, Weets I, Gorus FK; Belgian Diabetes Registry.

Diabetes. 2013 Apr;62(4):1345-50. doi: 10.2337/db12-0747. Epub 2012 Nov 16.

36.

Immune responses against islet allografts during tapering of immunosuppression--a pilot study in 5 subjects.

Huurman VA, van der Torren CR, Gillard P, Hilbrands R, van der Meer-Prins EP, Duinkerken G, Gorus FK, Claas FH, Keymeulen B, Roelen DL, Pipeleers DG, Roep BO.

Clin Exp Immunol. 2012 Aug;169(2):190-8. doi: 10.1111/j.1365-2249.2012.04605.x.

37.

Enhanced anti-serpin antibody activity inhibits autoimmune inflammation in type 1 diabetes.

Czyzyk J, Henegariu O, Preston-Hurlburt P, Baldzizhar R, Fedorchuk C, Esplugues E, Bottomly K, Gorus FK, Herold K, Flavell RA.

J Immunol. 2012 Jun 15;188(12):6319-27. doi: 10.4049/jimmunol.1200467. Epub 2012 May 16.

38.

An important minority of prediabetic first-degree relatives of type 1 diabetic patients derives from seroconversion to persistent autoantibody positivity after 10 years of age.

Vermeulen I, Weets I, Costa O, Asanghanwa M, Verhaeghen K, Decochez K, Ruige J, Casteels K, Wenzlau J, Hutton JC, Pipeleers DG, Gorus FK; Belgian Diabetes Registry.

Diabetologia. 2012 Feb;55(2):413-20. doi: 10.1007/s00125-011-2376-1. Epub 2011 Nov 18.

39.

Clusters of conserved beta cell marker genes for assessment of beta cell phenotype.

Martens GA, Jiang L, Hellemans KH, Stangé G, Heimberg H, Nielsen FC, Sand O, Van Helden J, Van Lommel L, Schuit F, Gorus FK, Pipeleers DG.

PLoS One. 2011;6(9):e24134. doi: 10.1371/journal.pone.0024134. Epub 2011 Sep 2. Erratum in: PLoS One. 2012;7(1). doi: 10.1371/annotation/a91571a6-acbb-456f-bcc5-f4a431e28516. PLoS One. 2012;7(1). doi:10.1371/annotation/13c6d084-a8fd-4019-a3cf-12a0d8abe309.. Van Lommel, Leentje [added], Schuit, Frans [added]. PLoS One. 2012;7(1). doi:10.1371/annotation/4aae21a9-e176-4feb-9f15-103b265d3335. PLoS One. 2012;7(1). doi:10.1371/annotation/7aa0ff33-5660-4b56-889a-4b86a273d522.

40.

Long-term stability of clinical laboratory data: sodium as benchmark.

Stepman HC, Stöckl D, Stove V, Fiers T, Couck P, Gorus F, Thienpont LM.

Clin Chem. 2011 Nov;57(11):1616-7. doi: 10.1373/clinchem.2011.168195. Epub 2011 Aug 30. No abstract available.

41.

Contribution of antibodies against IA-2β and zinc transporter 8 to classification of diabetes diagnosed under 40 years of age.

Vermeulen I, Weets I, Asanghanwa M, Ruige J, Van Gaal L, Mathieu C, Keymeulen B, Lampasona V, Wenzlau JM, Hutton JC, Pipeleers DG, Gorus FK; Belgian Diabetes Registry.

Diabetes Care. 2011 Aug;34(8):1760-5. doi: 10.2337/dc10-2268. Epub 2011 Jun 29.

42.

Protein markers for insulin-producing beta cells with higher glucose sensitivity.

Martens GA, Jiang L, Verhaeghen K, Connolly JB, Geromanos SG, Stangé G, Van Oudenhove L, Devreese B, Hellemans KH, Ling Z, Van Schravendijk C, Pipeleers DG, Vissers JP, Gorus FK.

PLoS One. 2010 Dec 6;5(12):e14214. doi: 10.1371/journal.pone.0014214.

43.

Use of likelihood ratios improves interpretation of laboratory testing for pulmonary sarcoidosis.

De Smet D, Martens GA, Berghe BV, Meysman M, Heylen O, Gorus FK, De Waele M.

Am J Clin Pathol. 2010 Dec;134(6):939-47. doi: 10.1309/AJCPNC7STHG0FWMP.

PMID:
21088158
44.

Association of IL-2RA/CD25 with type 1 diabetes in the Belgian population.

Aminkeng F, Weets I, Van Autreve JE, Koeleman BP, Quartier E, Van Schravendijk C, Gorus FK, Van der Auwera BJ; Belgian Diabetes Registry.

Hum Immunol. 2010 Dec;71(12):1233-7. doi: 10.1016/j.humimm.2010.09.006. Epub 2010 Sep 16.

PMID:
20849903
45.

Development of a multipurpose time-resolved fluorescence immunoassay for rat insulin.

van Genderen FT, Gorus FK, Vermeulen I, Vekens EM, De Pauw PE, Pipeleers DG, Van Schravendijk C.

Anal Biochem. 2010 Sep 1;404(1):8-13. doi: 10.1016/j.ab.2010.04.024. Epub 2010 Apr 24.

PMID:
20417610
46.

Beta-cell replication is increased in donor organs from young patients after prolonged life support.

In't Veld P, De Munck N, Van Belle K, Buelens N, Ling Z, Weets I, Haentjens P, Pipeleers-Marichal M, Gorus F, Pipeleers D.

Diabetes. 2010 Jul;59(7):1702-8. doi: 10.2337/db09-1698. Epub 2010 Apr 22.

47.

Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass.

Keymeulen B, Walter M, Mathieu C, Kaufman L, Gorus F, Hilbrands R, Vandemeulebroucke E, Van de Velde U, Crenier L, De Block C, Candon S, Waldmann H, Ziegler AG, Chatenoud L, Pipeleers D.

Diabetologia. 2010 Apr;53(4):614-23. Epub 2010 Jan 14.

PMID:
20225393
48.

Predictive power of screening for antibodies against insulinoma-associated protein 2 beta (IA-2beta) and zinc transporter-8 to select first-degree relatives of type 1 diabetic patients with risk of rapid progression to clinical onset of the disease: implications for prevention trials.

De Grijse J, Asanghanwa M, Nouthe B, Albrecher N, Goubert P, Vermeulen I, Van Der Meeren S, Decochez K, Weets I, Keymeulen B, Lampasona V, Wenzlau J, Hutton JC, Pipeleers D, Gorus FK; Belgian Diabetes Registry.

Diabetologia. 2010 Mar;53(3):517-24. doi: 10.1007/s00125-009-1618-y. Epub 2009 Nov 29.

PMID:
20091020
49.

Hyperglycaemic clamp test for diabetes risk assessment in IA-2-antibody-positive relatives of type 1 diabetic patients.

Vandemeulebroucke E, Keymeulen B, Decochez K, Weets I, De Block C, Féry F, Van de Velde U, Vermeulen I, De Pauw P, Mathieu C, Pipeleers DG, Gorus FK; Belgian Diabetes Registry.

Diabetologia. 2010 Jan;53(1):36-44. doi: 10.1007/s00125-009-1569-3. Epub 2009 Nov 7.

50.

Insulin treatment in IA-2A-positive relatives of type 1 diabetic patients.

Vandemeulebroucke E, Gorus FK, Decochez K, Weets I, Keymeulen B, De Block C, Tits J, Pipeleers DG, Mathieu C; Belgian Diabetes Registry.

Diabetes Metab. 2009 Sep;35(4):319-27. doi: 10.1016/j.diabet.2009.02.005. Epub 2009 Jul 31.

PMID:
19647467

Supplemental Content

Support Center